Tag: Accelerated approval 2023

Home / Accelerated approval 2023

Categories

Repotrectinib has received accelerated approval from the USFDA for adult and pediatric patients with NTRK gene fusion-positive solid tumors

  June 2024: The Food and Drug Administration (FDA) has given accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for the treatment of solid tumors in adult and pedia...
accelerated-approval-2023

Scan the code